Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells

Ran Yi Liu, Zizheng Dong, Jianguo Liu, Ling Zhou, Wenlin Huang, Sok Kean Khoo, Zhongfa Zhang, David Petillo, Bin Tean Teh, Chao Nan Qian, Jian Ting Zhang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin- sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNAdamage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma. Mol Cancer Ther; 12(10); 2157-66.

Original languageEnglish (US)
Pages (from-to)2157-2166
Number of pages10
JournalMolecular cancer therapeutics
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Aspartate-Ammonia Ligase
Cisplatin
Chorionic Gonadotropin
Platinum
Gene Expression Profiling
Chemoradiotherapy
Therapeutics
Nasopharyngeal carcinoma
matrix metalloproteinase 19
DNA Repair
Radiotherapy
Down-Regulation
Apoptosis
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. / Liu, Ran Yi; Dong, Zizheng; Liu, Jianguo; Zhou, Ling; Huang, Wenlin; Khoo, Sok Kean; Zhang, Zhongfa; Petillo, David; Teh, Bin Tean; Qian, Chao Nan; Zhang, Jian Ting.

In: Molecular cancer therapeutics, Vol. 12, No. 10, 01.10.2013, p. 2157-2166.

Research output: Contribution to journalArticle

Liu, RY, Dong, Z, Liu, J, Zhou, L, Huang, W, Khoo, SK, Zhang, Z, Petillo, D, Teh, BT, Qian, CN & Zhang, JT 2013, 'Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells', Molecular cancer therapeutics, vol. 12, no. 10, pp. 2157-2166. https://doi.org/10.1158/1535-7163.MCT-12-1190
Liu, Ran Yi ; Dong, Zizheng ; Liu, Jianguo ; Zhou, Ling ; Huang, Wenlin ; Khoo, Sok Kean ; Zhang, Zhongfa ; Petillo, David ; Teh, Bin Tean ; Qian, Chao Nan ; Zhang, Jian Ting. / Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. In: Molecular cancer therapeutics. 2013 ; Vol. 12, No. 10. pp. 2157-2166.
@article{cb6f13647d6d4fbfa989924994b3f8f8,
title = "Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells",
abstract = "Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin- sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNAdamage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma. Mol Cancer Ther; 12(10); 2157-66.",
author = "Liu, {Ran Yi} and Zizheng Dong and Jianguo Liu and Ling Zhou and Wenlin Huang and Khoo, {Sok Kean} and Zhongfa Zhang and David Petillo and Teh, {Bin Tean} and Qian, {Chao Nan} and Zhang, {Jian Ting}",
year = "2013",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-12-1190",
language = "English (US)",
volume = "12",
pages = "2157--2166",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells

AU - Liu, Ran Yi

AU - Dong, Zizheng

AU - Liu, Jianguo

AU - Zhou, Ling

AU - Huang, Wenlin

AU - Khoo, Sok Kean

AU - Zhang, Zhongfa

AU - Petillo, David

AU - Teh, Bin Tean

AU - Qian, Chao Nan

AU - Zhang, Jian Ting

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin- sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNAdamage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma. Mol Cancer Ther; 12(10); 2157-66.

AB - Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin- sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNAdamage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma. Mol Cancer Ther; 12(10); 2157-66.

UR - http://www.scopus.com/inward/record.url?scp=84885605346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885605346&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-1190

DO - 10.1158/1535-7163.MCT-12-1190

M3 - Article

C2 - 23956056

AN - SCOPUS:84885605346

VL - 12

SP - 2157

EP - 2166

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -